184 related articles for article (PubMed ID: 36672148)
21. The nuclear import of protein kinase D3 requires its catalytic activity.
Rey O; Papazyan R; Waldron RT; Young SH; Lippincott-Schwartz J; Jacamo R; Rozengurt E
J Biol Chem; 2006 Feb; 281(8):5149-57. PubMed ID: 16380377
[TBL] [Abstract][Full Text] [Related]
22. HER2/ErbB2 activates HSF1 and thereby controls HSP90 clients including MIF in HER2-overexpressing breast cancer.
Schulz R; Streller F; Scheel AH; Rüschoff J; Reinert MC; Dobbelstein M; Marchenko ND; Moll UM
Cell Death Dis; 2014 Jan; 5(1):e980. PubMed ID: 24384723
[TBL] [Abstract][Full Text] [Related]
23. Inhibiting the HSP90 chaperone destabilizes macrophage migration inhibitory factor and thereby inhibits breast tumor progression.
Schulz R; Marchenko ND; Holembowski L; Fingerle-Rowson G; Pesic M; Zender L; Dobbelstein M; Moll UM
J Exp Med; 2012 Feb; 209(2):275-89. PubMed ID: 22271573
[TBL] [Abstract][Full Text] [Related]
24. Taxotere-induced inhibition of human endothelial cell migration is a result of heat shock protein 90 degradation.
Murtagh J; Lu H; Schwartz EL
Cancer Res; 2006 Aug; 66(16):8192-9. PubMed ID: 16912198
[TBL] [Abstract][Full Text] [Related]
25. A phase II trial of ganetespib, a heat shock protein 90 Hsp90) inhibitor, in patients with docetaxel-pretreated metastatic castrate-resistant prostate cancer (CRPC)-a prostate cancer clinical trials consortium (PCCTC) study.
Thakur MK; Heilbrun LK; Sheng S; Stein M; Liu G; Antonarakis ES; Vaishampayan U; Dzinic SH; Li X; Freeman S; Smith D; Heath EI
Invest New Drugs; 2016 Feb; 34(1):112-8. PubMed ID: 26581400
[TBL] [Abstract][Full Text] [Related]
26. Characterization of a novel novobiocin analogue as a putative C-terminal inhibitor of heat shock protein 90 in prostate cancer cells.
Matthews SB; Vielhauer GA; Manthe CA; Chaguturu VK; Szabla K; Matts RL; Donnelly AC; Blagg BS; Holzbeierlein JM
Prostate; 2010 Jan; 70(1):27-36. PubMed ID: 19739131
[TBL] [Abstract][Full Text] [Related]
27. Targeted inhibition of Hsp90 by ganetespib is effective across a broad spectrum of breast cancer subtypes.
Friedland JC; Smith DL; Sang J; Acquaviva J; He S; Zhang C; Proia DA
Invest New Drugs; 2014 Feb; 32(1):14-24. PubMed ID: 23686707
[TBL] [Abstract][Full Text] [Related]
28. 17-ABAG, a novel geldanamycin derivative, inhibits LNCaP-cell proliferation through heat shock protein 90 inhibition.
Lin Z; Peng R; Li Z; Wang Y; Lu C; Shen Y; Wang J; Shi G
Int J Mol Med; 2015 Aug; 36(2):424-32. PubMed ID: 26059743
[TBL] [Abstract][Full Text] [Related]
29. [FAK/c-Src signaling pathway mediates the expression of cell surface HSP90 in cultured human prostate cancer cells and its association with their invasive capability].
Liu XG; Guo Y; Yan ZQ; Guo MY; Zhang ZG; Guo CA
Zhonghua Zhong Liu Za Zhi; 2011 May; 33(5):340-4. PubMed ID: 21875461
[TBL] [Abstract][Full Text] [Related]
30. Reduced FRG1 expression promotes prostate cancer progression and affects prostate cancer cell migration and invasion.
Tiwari A; Mukherjee B; Hassan MK; Pattanaik N; Jaiswal AM; Dixit M
BMC Cancer; 2019 Apr; 19(1):346. PubMed ID: 30975102
[TBL] [Abstract][Full Text] [Related]
31. UDP glucuronosyltransferase 1A expression levels determine the response of colorectal cancer cells to the heat shock protein 90 inhibitor ganetespib.
Landmann H; Proia DA; He S; Ogawa LS; Kramer F; Beißbarth T; Grade M; Gaedcke J; Ghadimi M; Moll U; Dobbelstein M
Cell Death Dis; 2014 Sep; 5(9):e1411. PubMed ID: 25210794
[TBL] [Abstract][Full Text] [Related]
32. Capillarisin blocks prostate-specific antigen expression on activation of androgen receptor in prostate carcinoma cells.
Tsui KH; Chang YL; Feng TH; Hou CP; Lin YH; Yang PS; Lee BW; Juang HH
Prostate; 2018 Mar; 78(4):242-249. PubMed ID: 29164633
[TBL] [Abstract][Full Text] [Related]
33. Protein kinase d isoforms differentially modulate cofilin-driven directed cell migration.
Döppler H; Bastea LI; Borges S; Spratley SJ; Pearce SE; Storz P
PLoS One; 2014; 9(5):e98090. PubMed ID: 24840177
[TBL] [Abstract][Full Text] [Related]
34. A novel HSP90 inhibitor delays castrate-resistant prostate cancer without altering serum PSA levels and inhibits osteoclastogenesis.
Lamoureux F; Thomas C; Yin MJ; Kuruma H; Fazli L; Gleave ME; Zoubeidi A
Clin Cancer Res; 2011 Apr; 17(8):2301-13. PubMed ID: 21349995
[TBL] [Abstract][Full Text] [Related]
35. Cell Stress Induced Stressome Release Including Damaged Membrane Vesicles and Extracellular HSP90 by Prostate Cancer Cells.
Eguchi T; Sogawa C; Ono K; Matsumoto M; Tran MT; Okusha Y; Lang BJ; Okamoto K; Calderwood SK
Cells; 2020 Mar; 9(3):. PubMed ID: 32204513
[TBL] [Abstract][Full Text] [Related]
36. Restricting direct interaction of CDC37 with HSP90 does not compromise chaperoning of client proteins.
Smith JR; de Billy E; Hobbs S; Powers M; Prodromou C; Pearl L; Clarke PA; Workman P
Oncogene; 2015 Jan; 34(1):15-26. PubMed ID: 24292678
[TBL] [Abstract][Full Text] [Related]
37. Hsp90 is an essential regulator of EphA2 receptor stability and signaling: implications for cancer cell migration and metastasis.
Annamalai B; Liu X; Gopal U; Isaacs JS
Mol Cancer Res; 2009 Jul; 7(7):1021-32. PubMed ID: 19567782
[TBL] [Abstract][Full Text] [Related]
38. TGF-β Effects on Prostate Cancer Cell Migration and Invasion Require FosB.
Barrett CS; Millena AC; Khan SA
Prostate; 2017 Jan; 77(1):72-81. PubMed ID: 27604827
[TBL] [Abstract][Full Text] [Related]
39. The co-chaperone p23 promotes prostate cancer motility and metastasis.
Cano LQ; Lavery DN; Sin S; Spanjaard E; Brooke GN; Tilman JD; Abroaf A; Gaughan L; Robson CN; Heer R; Mauri F; de Rooij J; Driouch K; Bevan CL
Mol Oncol; 2015 Jan; 9(1):295-308. PubMed ID: 25241147
[TBL] [Abstract][Full Text] [Related]
40. High-throughput screens identify HSP90 inhibitors as potent therapeutics that target inter-related growth and survival pathways in advanced prostate cancer.
Jansson KH; Tucker JB; Stahl LE; Simmons JK; Fuller C; Beshiri ML; Agarwal S; Fang L; Hynes PG; Alilin AN; Lake R; Abbey YC; Cawley J; Tice CM; Yin J; McKnight C; Klummp-Thomas C; Zhang X; Guha R; Hoover S; Simpson RM; Nguyen HM; Corey E; Thomas CJ; Proia DA; Kelly K
Sci Rep; 2018 Nov; 8(1):17239. PubMed ID: 30467317
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]